Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Sermorelin + GHRP-2

GH Optimization Combination

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

The specific sermorelin (GHRH analog) plus GHRP-2 (pralmorelin) combination is a compounded growth-hormone-secretagogue stack marketed off-label by anti-aging and TRT clinics, and it has no randomized controlled trial of the combination reporting clinical outcomes. Short-term human secretagogue studies show the components raise GH and IGF-1 pulses, a marker signal only, and a 2017 review (Sinha et al., PMC5632578) states that few studies examine clinically significant endpoints such as body composition or quality of life and that long-term safety including cancer and mortality data is lacking, so an anecdotal/mechanistic grade of 1 is honest.

FDA
No FDA-approved sermorelin+GHRP-2 combination product. Prepared as an off-label compounded stack. Sermorelin was FDA-approved as Geref in 1997 and discontinued in 2008 for commercial reasons; GHRP-2 (pralmorelin) was never FDA-approved and sits in Category 3 of the interim 503A bulks list, while related GH-secretagogue peptides have been removed from Category 2 and referred to PCAC review.
WADA
Prohibited at all times under S2.2.4 (growth hormone releasing factors): both the GHRH analog sermorelin and the GHRP GHRP-2/pralmorelin are named on the WADA Prohibited List.

Reference only. Not medical advice.

What can go wrong

WADA-prohibited at all times; unapproved off-label compounded stack with no combination outcome RCT; raises IGF-1, and GHRP-2 transiently raises cortisol and prolactin.

Talk to a clinician before taking this, particularly if you have any history of cancer. The Atlas can tell you what has been studied about Sermorelin + GHRP-2. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A common compounding-pharmacy combination pairing the GHRH analog sermorelin with the secretagogue GHRP-2 for a synergistic growth-hormone pulse. The more conservative cousin of the CJC-1295/Ipamorelin stack.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • GH optimization
  • Body composition
  • Sleep quality

How it is supposed to work

This is a growth-hormone secretagogue combination pairing sermorelin, a GHRH analog that raises the baseline growth-hormone signal, with GHRP-2, a ghrelin-mimetic that sharpens the pulses through a separate receptor. Hitting both pathways at once produces a larger growth-hormone release than either alone, the same two-pathway logic as the popular CJC-1295 plus ipamorelin stack. GHRP-2 is more potent than the older GHRP-6 but also more likely to raise hunger, cortisol and prolactin.

The combination pairs Sermorelin, the active core of growth-hormone-releasing hormone, with GHRP-2, a potent synthetic growth-hormone-releasing peptide that acts on the ghrelin receptor. GHRP-2 is one of the stronger releasing peptides, and unlike the highly selective ipamorelin it also produces moderate increases in cortisol, prolactin and appetite.

Type
GHRH plus GHRP stack
Components
Sermorelin and GHRP-2
Selectivity
Lower than ipamorelin
Extra effects
Cortisol, prolactin, appetite
Approved
No
Sport
Prohibited

Another GHRH-Plus-GHRP Stack, Less Selective Than CJC-Ipamorelin

Sermorelin plus GHRP-2 is one more entry in the growth-hormone-releasing family, and it is best read against the CJC-1295 plus ipamorelin stack covered elsewhere, because the logic is identical and only the components differ. Combining a releasing-hormone analog with a releasing peptide is genuinely synergistic, producing a bigger growth-hormone pulse than either part alone, which is why these pairings are popular. The meaningful distinction here is selectivity: GHRP-2 is potent but less clean than ipamorelin, nudging cortisol, prolactin and appetite upward as well, so the side-effect profile is a little broader. Everything else is the family’s: the same downstream growth-factor elevation and its unresolved cancer-risk question, no approval for these uses, prohibition in sport, and reliance on gray-market or compounded supply. It is a less selective version of a familiar stack.

Safety in detail

Marketed by anti-aging and TRT clinics as growth-hormone optimization, this combination has no randomized controlled trial of the paired regimen and rests on short-term GH/IGF-1 marker data for the individual secretagogues. Long-term safety, including cancer and mortality signals, is unstudied, and the components are subject to active FDA compounding restrictions.

  • Sustained growth-hormone elevation can cause insulin resistance, fluid retention and joint pain, as with all secretagogues.
  • GHRP-2 specifically tends to increase hunger and can raise cortisol and prolactin, less cleanly selective than ipamorelin.
  • Growth-hormone secretagogues are considered unsafe for anyone with active or prior cancer.
  • Prohibited in sport at all times under WADA as growth-hormone secretagogues.
  • Neither component is FDA-approved in this use; gray-market and compounded supply dominate.

Children and teenagers

Sermorelin plus GHRP-2 has no validated pediatric use and is an unapproved injected peptide combination. There is no appropriate pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Sermorelin plus GHRP-2 reaches users through the same gray-market and compounding channels as the rest of the growth-hormone peptide family. There is no approved product for these uses, and its market is body composition and growth-hormone optimization.

How we got here

Sermorelin originated as GRF 1-29, the shortest fully active N-terminal fragment of the 44-amino-acid human growth-hormone-releasing hormone characterized in the early 1980s, and reached market as Geref with FDA approval in 1997 for pediatric growth-hormone deficiency before its manufacturer discontinued it in 2008 for commercial reasons. GHRP-2 was developed separately from the growth-hormone-releasing peptide series (GHRP-1 through GHRP-6) that grew out of enkephalin-derived met-enkephalin analog work in the 1980s and 1990s, and it carries the INN pralmorelin plus the developmental codes KP-102 and GPA-748. The paired sermorelin-plus-GHRP-2 product is not an approved combination drug and was not developed as one; it is a compounding-pharmacy and anti-aging/TRT-clinic construct that stacks a GHRH analog with a GHRP to amplify the growth-hormone pulse, sold off-label and now sitting inside the FDA's ongoing 503A/503B bulk-substance restrictions on GH-secretagogue peptides.

The Sermorelin plus GHRP-2 pairing reflects the established physiology that combining a growth-hormone-releasing hormone with a releasing peptide amplifies growth-hormone output. GHRP-2 was among the potent early releasing peptides, and the stack became a gray-market staple alongside the cleaner CJC-1295 plus ipamorelin combination.

The numbers behind the grade

Type
GH secretagogue stack
Components
Sermorelin + GHRP-2
Pathways
GHRH + ghrelin
WADA
Prohibited
Approved
No
Note
GHRP-2 raises appetite

The people taking it

A common growth-hormone secretagogue stack in anti-aging and bodybuilding, an alternative to CJC-1295 plus ipamorelin, with the same evidence gap.

Its users are the body-composition and growth-hormone-optimization crowd in the gray-market and compounding peptide community, choosing a potent stack and accepting its broader side effects.

Used off-label and gray-market to raise growth hormone for body composition, recovery and anti-aging, as an alternative to other secretagogue stacks. Prohibited in sport.

Set against the alternatives

Sermorelin plus GHRP-2 is the less selective cousin of the CJC-1295 plus ipamorelin stack, swapping in a shorter-acting releasing hormone and a stronger but messier releasing peptide. Against GHRP-6, GHRP-2 is similarly potent but with somewhat less extreme appetite stimulation, and against Tesamorelin, the one approved GHRH analog, the whole stack is the unapproved gray-market alternative. Its identity is defined by the selectivity tradeoff relative to the cleaner stack.

What we do not know

  • Whether raising growth hormone this way produces any of the claimed benefits in proper trials.
  • How GHRP-2’s appetite, cortisol and prolactin effects weigh against its potency.
  • What the long-term safety of sustained growth-hormone elevation is.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Available through compounding pharmacies with a prescription or as gray-market research material. As with the CJC-1295 plus ipamorelin stack, the benefits are unproven; anyone wanting a regulated GHRH analog should ask a clinician about tesamorelin instead.

Sourced through compounding pharmacies and, more loosely, Chinese research-chemical synthesis, with the usual quality caveats for the gray-market route.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Sermorelin + GHRP-2.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Supply chain. We have not mapped where it is made.
  • What could change. No forward-looking summary yet.

Sources

The studies that matter

  • GHRH-plus-GHRP synergy1990s-2000s

    Combining a GHRH analog with a GHRP produces a synergistic growth-hormone pulse, the established basis for these stacks.

  • GHRP-2 pharmacology1990s-2000s

    GHRP-2 is a well-characterized, potent growth-hormone secretagogue that also stimulates appetite and modestly raises cortisol and prolactin.

  • Outcome trials for the combonone

    No human trials show the combination delivers the muscle, fat-loss or anti-aging benefits it is marketed for.